Email Us
Call Us
AUSTIN, Texas – April 22, 2025 – Glioblastoma remains among the most therapeutically resistant human cancers, characterized by diffuse invasion, resistance to conventional treatment, and high mortality. Progress depends on models that reproduce those properties rather than models chosen for convenience of growth. Altogen Labs validated glioblastoma models include published documentation that covers cell handling under aseptic conditions, implantation, acclimatization, tumor measurement and clinical observation schedules, humane endpoint criteria defined in the study design, and termination. Following tumor resection, tumors are weighed and digitally imaged, and collected samples are frozen, fixed in 10% neutral buffered formalin for histology, or stabilized in RNAlater for nucleic acid work. Advanced monitoring options include bioluminescence imaging and MRI for real-time assessment of tumor progression and treatment response, complemented by immunohistochemistry, molecular profiling, survival analysis, and histopathological evaluation.
The A172 model sits within a brain cancer portfolio that also includes U87, U87-Luc, U251, U118, LN229, SF268, SF295, SF539, SNB-19, SNB-75, and SK-N-AS, available in subcutaneous and orthotopic configurations. Cell line-derived xenografts provide reproducible, cost-effective platforms for tumor biology and drug response; patient-derived xenografts preserve the genetic and histological character of the originating tumor for higher translational relevance. Altogen Labs offers both, and helps sponsors choose between them. Complementary services include custom cell line engineering with stable protein overexpression or RNAi-mediated gene silencing, mRNA expression analysis by RT-PCR, and protein quantification by automated capillary Western.
About Altogen Labs Altogen Labs is a professional, experienced, and highly reputable GLP-compliant contract research organization providing preclinical research and biology CRO services worldwide, with a large collection of in-house validated xenograft models (CDX, PDX, syngeneic, organoids, NAMs) and extensive experience in efficacy xenograft and safety toxicology studies.
Contact Information: Altogen Labs | 11200 Menchaca Rd, Bldg 2, Suite 203 | Austin, TX 78748 USA Tel: 512-433-6177 | Email: info@altogenlabs.com | Web: altogenlabs.com